Kornimate/medical-research-clean huggingface dataset:
cbt-i chatbot for youth

Conditions: Insomnia

Summary: insomnia is prevalent in youth, and it associates with depression and other psychiatric disorders, leading to increased mental health burden. cognitive behavioral therapy for insomnia (cbt-i) is recommended as first-line treatment for insomnia. digital tools have been employed to automate mental health interventions, in order to address deterrents such as clinician shortage, limited appointment availability, high cost, and stigma of seeking help. digital cbt-i is shown to be effective in treating insomnia. future digital intervention will incorporate patient-centered design, input from key stakeholders, and new understandings of behavior change. artificial intelligence (ai)-powered chatbots are utilized in different industries for better customer experience. ai chatbot is also utilized in the mental health industry to extend the boundary of digital interventions from accommodating didactic and informational content to providing interactive, intelligent, and most importantly, patient-centered conversational agents. some famous ai mental health chatbots in western societies were developed to give tailored feedback, respond to emotions that a user expresses, and encourage users to complete an intervention. this study will investigate the effect of a cbt-i chatbot on insomnia to provide further evidence on mental health chatbot.


Eligibility criteria:
inclusion criteria: * score 8 or higher on the insomnia severity index (isi) * between 18 and 35 years old * read and type chinese * own a smartphone * have consistent internet access to their smartphone exclusion criteria: * have a self-reported diagnosis of any psychiatric disorder(s) * have been on regular medication(s) in the past month * do not have instant messaging app(s) will be excluded.

Keywords: chatbot youth insomnia cbt-i rct
vcrc longitudinal protocol for aortitis

Conditions: Aortitis

Summary: the term 'aortitis' refers to inflammation of the aorta. aortitis is known to occur in a variety of vasculitides and connective tissue diseases, such as giant cell arteritis (gca), takayasu arteritis (tak), rheumatoid arthritis, and spondyloarthropathies, among others. this study will establish a longitudinal cohort for these diseases.

this study will develop a longitudinal cohort of patients with different types of aortitis to systematically study the natural history, optimal treatments, and outcomes in this group of diseases. this will provide a resource for future studies and for identification of new biomarkers of aortitis for purposes of diagnosis, disease activity measurement, disease damage assessment, determination of disease states, and evaluation of treatment response.

Eligibility criteria:
inclusion criteria: subjects will be included if they meet one of the following criteria: 1. previous or current microscopic evidence of aortitis (active or healed) on surgical specimen obtained during aortic resection 2. previous or current radiographic aortitis that could include circumferential aortic wall thickening of at least 3mm on ct or mri or increased pet fdg uptake in the aorta at values equal to or greater than the liver, in absence of an alternative explanation for the radiographic findings. exclusion 1. subjects already enrolled in one of the other vcrc longitudinal cohorts: 5502, 5503, 5504, 5505, and 5506. 2. inability of participants (or their guardians in the case of children) to give informed consent and to sign the consent form.

Keywords: idiopathic aortitis isolated aortitis vasculitis
demonstration study of the effect of the transcranial direct current stimulation (tdcs) on depressed patients

Conditions: Depression

Summary: purpose of research: it aims to demonstrate the effectiveness of transcranial direct current stimulation (tdcs) in the clinical domain for patients with depression and to optimize home-based e-medication technology.

as a home-based clinical empirical study of transcranial direct current stimulation for depressed patients, male and female subjects aged 19 to 65 who meet the criteria for mild and moderate major depressive disorder (mdd) were enrolled, and real-world data (rwd) was obtained through self-application of transcranial direct current stimulation (tdcs) at home for 6 weeks. this is a study that secures and derives real-world evidence (rwe) that can be applied to clinical practice.

Eligibility criteria:
inclusion criteria: * male and female aged 19 to 65 with mild and moderate major depressive disorder (mdd) exclusion criteria: * those diagnosed with post-traumatic stress disorder (ptsd), obsessive compulsive disorder (ocd), bipolar or psychotic major depressive disorder, high suicide risk, electroencephalography (eeg) and dc stimulation electrode attachment problems (such as scalp deformity, inflammatory response or other dermatological problems), transcranial direct current stimulation (tdcs) medical device taboos (such as head metal plate insertion), clinical trials that have been inadequate for clinical trials
waiting time in the premedication room on anxiety

Conditions: Total Anesthetic Consumption

Summary: the primary purpose of the study is to determine the total anesthetic consumption required to reach the optimal depth of anesthesia (bis 50) depending on the anxiety of the waiting period in the preoperative waiting room and the degree of anxiety.


Eligibility criteria:
inclusion criteria: * being in the age group of 18 and over * being literate and able to communicate * individuals will have surgery in ent, urology, brain surgery, orthopedics, general surgery, plastic surgery, cvs and gynecology and obstetrics departments. * agreeing to participate in the research voluntarily exclusion criteria: * alcohol or drug use * history of psychiatric illness * central nervous system disease * use of psychotropic medication * pregnancy * lack of vision, hearing
study comparing the p200txe and p200dtx

Conditions: Retinal Disease

Summary: the study evaluates image quality between two devices.


Eligibility criteria:
inclusion criteria: 1. male or female subjects 22 years of age or older who have full legal capacity to volunteer on the date the informed consent is signed; 2. subjects who can follow the instructions by the clinical staff at the clinical site, 3. subjects who agree to participate in the study; 4. subjects diagnosed with retinal pathology. example of pathologies may include but are not limited to age-related macular degeneration, diabetic macular edema, diabetic retinopathy, macular hole, epiretinal membrane, central serous retinopathy, and others as confirmed by the investigator; exclusion criteria: 1. subjects unable to tolerate ophthalmic imaging; 2. subjects with ocular media not sufficiently clear to obtain acceptable images;
study with amitriptylin to evaluate the efficacy of melatonin in treatment of migraine

Conditions: Migraine

Summary: the purpose of this study is to determine the effectiveness of melatonin 3 mg compared to placebo and amitriptyline 25 mg in the preventive treatment of migraine.

the investigators propose a study of patients with migraine (episodic) with or without aura, according to the criteria of the international headache society (ihs) 2004. this will be a randomized clinical trial, prospective, double-blind, placebo-controlled, comparing the efficacy of melatonin 3 mg and amitriptyline 25 mg for migraine prevention. the length of the inclusion of the study will be 24 months. this study's general objective is: to evaluate the effectiveness of melatonin in the preventive treatment of migraine and compare it to placebo and amitriptyline.

Eligibility criteria:
inclusion criteria: * man or woman 18 to 65 years of age. * meets diagnostic criteria criteria of international headache society (ihs) 2004 (2) for migraine with and / or without aura. * frequency from 2 to 8 migraine attacks per month * top of crisis over a year and age of onset less than 50 years of age. * patients want to participate in the study, and able to give informed consent. * if women, the patient must be willing to use an acceptable method of birth control (eg, a hormonal contraceptive, intrauterine device, diaphragm with spermicide or condom with spermicide, or refer abstinence). * patient able and willing to remain on their medications throughout the study. * accept the guidelines of the study by filling out the diary and clinical scales. exclusion criteria: * any medical condition that places the patient at risk with its exposure to melatonin or amitryptiline * use of alcohol and drugs. * be receiving prophylactic medication in the last three months. * history of hemiplegic migraine, basilar, ophthalmoplegic or stroke. * headache secondary to head trauma or a whiplash neck injury (whiplash). * pregnant or breastfeeding. women planning to become pregnant or of childbearing age without acceptable method of contraception. * women who began taking oral contraceptives or who switched their oral contraceptive regimen in the 6 months prior to the start of the study. * allergy or known hypersensitivity to study medication or its components. * participation in another clinical study one month before inclusion.

Keywords: amitriptyline placebo melatonin migraine headache drug therapy preventive treatment of migraine
efficacy and safety of vildagliptin in combination with insulin in patients with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: many people with type 2 diabetes cannot maintain their target blood glucose levels on a single therapy. the purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, in lowering overall blood glucose levels when added to insulin in people with type 2 diabetes who are not at target blood glucose levels on insulin alone.


Eligibility criteria:
inclusion criteria: * blood glucose criteria must be met * on a stable dose of insulin as defined by the protocol * body mass inde (bmi) in the range 22-45 exclusion criteria: * type 1 diabetes * pregnancy or lactation * evidence of serious diabetic complications * evidence of serious cardiovascular complications * laboratory value abnormalities as defined by the protocol * other protocol defined exclusion criteria may apply

Keywords: type 2 diabetes vildagliptin
a study to evaluate ibi112 in the treatment of subjects with moderate to severe plaque psoriasis

Conditions: Psoriasis

Summary: the purpose of this study is to evaluate the efficacy and safety of ibi112 administered in different dose regimens for the treatment of patients with plaque psoriasis


Eligibility criteria:
inclusion criteria * diagnosis of plaque-type psoriasis with or without psoriatic arthritis for at least 6 months prior to first administration of any study agent * must be a candidate for phototherapy or systemic treatment for psoriasis (either new to treatment or having had previous treatment) exclusion criteria * history of or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease * participant has history of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis * has received any therapeutic agent directly targeted to il-12, il-17, or il-23within 6 months of the first administration of study agent * has received any therapeutic agent directly targeted totnf-a within 3 months of the first administration of study agent * has received any conventional therapeutic agent within 1 months of the first administration of study agent * has received any topic therapeutic agent within 2 weeks of the first administration of study agent
regulation of endothelial progenitor cells by short-term exercise

Conditions: Aging; Exercise; Cardiovascular Disease

Summary: endothelial progenitor cells (epcs) are circulating cells released from bone marrow which are important for maintaining cardiovascular health. the prevalence of cardiovascular disease in older adults is associated with reduced circulating epc numbers. studies have shown reduced epc number and function in old vs. young individuals, and endurance exercise training increases epc number and function in young adults. oxidative stress adversely affects endothelial cells and preliminary evidence indicates that oxidative stress negatively affects epc function. conversely, regular exercise reduces markers of oxidative stress and may enhance epc function in older adults. the investigators hypothesize that older endurance-trained athletes and matched sedentary individuals will have markedly divergent epc function and that altering the physical activity levels of both groups will move them to intermediate points between these two extremes. the investigators also propose that the investigators can "mimic" the effect of exercise training on epc function in cell culture by altering intracellular levels of a key enzyme and a signaling molecule which the investigators have shown to regulate epc function with respect to exercise training in young individuals.


Eligibility criteria:
inclusion criteria: * 50-80 years of age, bmi = 18-35 kg/m2, non-smoking, women must be postmenopausal exclusion criteria: * history of cardiovascular/cerebrovascular disease, diabetes, cancer, renal, liver disease, hiv; uncontrolled hyperlipidemia/hypertension
sonobiopsy for noninvasive and sensitive detection of glioblastoma

Conditions: Glioblastoma; Glioblastoma Multiforme

Summary: this clinical study to evaluate sonobiopsy is significant because sonobiopsy will fundamentally enhance the clinician's insight into the molecular features of an intracranial lesion to tailor treatment approaches and optimize outcomes. in addition to the standard diagnostics of anatomic imaging and surgical histology, sonobiopsy has the potential to become the third pillar for brain tumor management by radically advancing the ability to easily and regularly acquire tumor genetic and molecular signatures. this enhanced capability will have a dramatic impact on patient survival and quality of life.


Eligibility criteria:
inclusion criteria: * must be newly diagnosed with a lesion in the brain with imaging characteristics consistent with glioblastoma multiforme. scan must have occurred no more than 28 days prior to enrollment. * lesion must be \> 3 cm in maximal dimension on mri. * lesion must be in the supratentorial space within 5 cm of the cortical surface. * lesion must be gadolinium enhancing. * low grade tumors and metastatic tumors * recurrent brain tumors and/or radiation necrosis * must be planning to undergo surgical resection of the tumor. * must be at least 18 years old. * patients with recurrent gbm who are planning to undergo surgical resection or laser ablation of the recurrent tumor. recurrence must be confirmed on mri performed no more than 28 days prior to enrollment. exclusion criteria: * contraindication to mri. * previous cranial surgery. * previous history of cancer and/or cancer treatments. * coagulopathy within 14 days of enrollment defined as pt/ptt outside of normal parameters and platelets \< 100,000/mcl. * physical skull defect of any kind. * ferrous material in the scalp or skull. * scalp or skin disease that limits contact with the ultrasound probe. * enrolled in another clinical trial where intervention is administered prior to surgery. * known hypersensitivity to polyethylene glycol. * known unstable cardiopulmonary condition (e.g. acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, serious ventricular arrhythmias).
an investigational immuno-therapy safety and effectiveness study of nivolumab in combination with brentuximab vedotin to treat non-hodgkin lymphomas

Conditions: Non-Hodgkin's Disease

Summary: the purpose of this study is to determine whether nivolumab, in combination with brentuximab vedotin, is safe and effective in patients with certain subtypes of non-hodgkin's lymphomas with cd30 expression that have not responded to treatment or have come back. the subtypes we are studying are diffuse large b-cell lymphoma (dlbcl), peripheral t-cell lymphoma (ptcl), cutaneous t-cell lymphoma (ctcl), primary mediastinal large b-cell lymphoma (pmbl) and mediastinal gray zone lymphoma (mgzl).


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * relapsed/refractory diffuse large b cell lymphoma (dlbcl), relapsed/refractory peripheral t cell lymphoma (ptcl) (all subtypes excluding anaplastic large cell lymphoma), relapsed/refractory cutaneous t cell lymphoma (ctcl) mycosis fungoides/sezary syndrome (mf/ss), relapsed/refractory primary mediastinal b lymphoma (pmbl), and relapsed/refractory mediastinal gray zone lymphoma (mgzl) * expression of cd30 * subjects must be 18 years or older (≥ 15 years for pmbl) exclusion criteria: * known central nervous system (cns) lymphomas; active cerebral/meningeal disease related to the underlying malignancy * active, known, or suspected autoimmune disease
efficacy of aclidinium bromide administered in chronic obstructive pulmonary disease (copd) patients

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: the main purpose of this study is to evaluate the efficacy, safety and tolerability of multiple doses of inhaled aclidinium bromide in moderate to severe copd patients.


Eligibility criteria:
inclusion criteria: * adult male and female patients aged 40 with stable moderate to severe copd (gold guidelines). * post-salbutamol (fev1) \< 80% and ≥ 30% of predicted normal value and post-salbutamol fev1/fvc \< 70%. * current or ex smokers of 10 pack-years. exclusion criteria: * patients with no history or current diagnosis of asthma. * no evidence of an exacerbation within 6 weeks prior to the screening visit. * no evidence of clinically significant respiratory and/or cardiovascular conditions or laboratory abnormalities. * no contraindication to use of anticholinergic drugs such as known symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma.

Keywords: copd antimuscarinic
pharmacokinetic study of dexmedetomidine after intra-nasal dosing in children

Conditions: Heart Disease

Summary: this research study is examining the absorption of the sedative dexmedetomidine (dex) in the blood when given by nasal spray. the study will help us determine the best dosing amount for children undergoing sedation or anesthesia with dex.

the study will be a prospective study of plasma concentrations after intranasal (1 µg/kg and 2µg/kg) and intravenous (1 µg /kg) dex to determine the early pharmacokinetics (maximum concentration (peak) and time to peak) and bioavailability of a single intranasal dose in pediatric patients. dexmedetomidine sedation is commonly utilized at cincinnati children's medical center (cchmc) and other pediatric institutions. this compound is delivered intravenously or intranasally for sedation in children with and without congenital heart disease. intranasal dex, though very effective for sedation, has significant variability in its onset and peak effect. patient care will be significantly improved if factors that determine this variability in onset and peak effect can be determined. investigators will determine the important early clinical variables of peak plasma dex concentration (tmax and cmax) and the 0 - 2 hour bioavailability of intranasal dex in children.

Eligibility criteria:
inclusion criteria: * children aged 6 - 48 months (inclusive) scheduled to receive anesthesia for elective cardiac surgery. * the subject must be a candidate to receive dex. a physician member of the division of cardiac anesthesiology, not involved in the study, will make this decision. * the subject's legally authorized representative has given written informed consent to participate in the study. exclusion criteria: * post-natal age (pna) \< 6 months * the subject is allergic to or has a contraindication to dex * severely depressed ventricular function (ejection fraction 30% or less) on preoperative echocardiogram * the subject has high risk cardiac conduction system disease at the discretion of the attending anesthesiologist or cardiologist. * the subject has a hemodynamically significant coarctation or other left heart outflow obstruction * the subject has received digoxin, beta-adrenergic antagonist, or calcium-channel antagonist on the day of the study * the subject has received dex within 1 week of the study date (information obtained from: parent or medical record) * subject have nasal/respiratory symptoms which in the opinion of the principal investigator, may affect intranasal drug absorption.

Keywords: pediatric sedation dexmedetomidine
upadacitinib for refractory ibd in asian children and elderly: age-stratified analysis

Conditions: Crohn&#39;s Disease (CD); Ulcerative Colitis (UC); Refractory Crohn&#39;s Disease; Refractory Ulcerative Colitis; Inflammatory Bowel Disease (IBD); Pediatric Crohn&#39;s Disease; Geriatric Ulcerative Colitis

Summary: this single-center, retrospective study aims to evaluate the effectiveness and safety of upadacitinib (upa) in asian pediatric patients with refractory crohn's disease (cd) and elderly patients with refractory ulcerative colitis (uc). the study will analyze data from 21 patients (11 children aged 9-17 with cd and 10 adults aged 60 and older with uc) treated at the sixth affiliated hospital of sun yat-sen university between january 2023 and december 2024. the primary objective is to assess the clinical remission rate and endoscopic response rate in both groups. secondary objectives include comparing treatment outcomes between the two age groups, exploring the impact of immunosenescence on upa efficacy in elderly uc patients, and analyzing the correlation between laboratory markers (crp, albumin) and clinical outcomes. this study is the first in asia to investigate the age-stratified efficacy of upadacitinib in pediatric cd and elderly uc patients. the findings will provide crucial real-world evidence to inform individualized treatment strategies for these specific populations. patients included in this study will have previously failed at least two biological therapies. data collected will include demographics, disease characteristics, prior treatment history, upa dosage and duration, clinical and endoscopic scores (pcdai/mayo, ses-cd/uceis), imaging results, laboratory values, and adverse events. the study is registered on clinicaltrials.gov (nct06274996). ethical considerations will be addressed through data anonymization and a waiver of informed consent due to the retrospective nature of the study.


Eligibility criteria:
inclusion criteria: * diagnosis of ibd according to the "consensus on diagnosis and treatment of inflammatory bowel disease (2023)"; failure of at least two prior biological therapies (anti-tnf/anti-integrin/il-12/23 inhibitors); complete baseline and follow-up data (at least 12 weeks)) exclusion criteria: * active infection, malignancy, severe cardiovascular disease, or hepatic/renal insufficiency; pregnancy or breastfeeding; use of other jak inhibitors within 30 days prior to baseline)